Psychotic Depression-Beyond the Antidepressant/Antipsychotic Combination

被引:14
|
作者
Nelson, Erik B. [1 ,2 ]
机构
[1] Univ Cincinnati, Acad Hlth Ctr, Dept Psychiat & Behav Neurosci, Cincinnati, OH 45267 USA
[2] Univ Cincinnati, Acad Hlth Ctr, Cincinnati VAMC, Cincinnati, OH 45267 USA
关键词
Psychotic depression; Major depression with psychotic features; Delusional depression; Psychotic mood disorders; Depressive subtypes; Nonpsychotic depression; Treatment; Antidepressant-antipsychotic combination; Antidepressant monotherapy; Antipsychotic monotherapy; Mineralocorticoid receptor; MR; Fludrocortisone; HPA axis dysregulation; Psychiatry; RANDOMIZED CONTROLLED-TRIAL; OPEN-LABEL TRIAL; MAJOR DEPRESSION; DELUSIONAL DEPRESSION; NONPSYCHOTIC DEPRESSION; UNIPOLAR DEPRESSION; FOLLOW-UP; PROGNOSTIC IMPORTANCE; ECT RESPONSE; MIFEPRISTONE;
D O I
10.1007/s11920-012-0315-6
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Psychotic depression is an identified subtype of major depression that has many features of a distinct psychiatric disorder. Recent studies support previous findings that psychotic depression is associated with a less favorable course of illness. Moreover, the presence of a single psychotic symptom appears to predict decreased responsiveness to antidepressant monotherapy. Recent studies also support biological differences between psychotic and non-psychotic depression. Previous findings of greater HPA axis dysregulation are supported by evidence of diminished cortisol suppression with the mineralocorticoid antagonist fludrocortisone in psychotic depression. Moreover, a functional neuroimaging study demonstrated greater activation in parahippocampal and tempoparietal regions in psychotic depression during a memory task. In support of several previous treatment studies, a recent meta-analysis of studies that compared an antidepressant-antipsychotic combination to antidepressants or antipsychotics alone found a therapeutic advantage with the combined treatment over monotherapy. A recent clinical trial suggests that mifepristone, a glucocorticoid antagonist, may be an effective adjunctive treatment for psychotic depression.
引用
收藏
页码:619 / 623
页数:5
相关论文
共 50 条
  • [31] Quetiapine in combination with citalopram in patients with unipolar psychotic depression
    Konstantinidis, A.
    Hrubos, W.
    Nirnberger, G.
    Windhager, E.
    Lehofer, M.
    Aschauer, H.
    Kasper, S.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (01): : 242 - 247
  • [32] Olanzapine-fluoxetine combination for psychotic major depression
    Dube, S
    Rothschild, A
    Andersen, SW
    Sanger, TM
    Clemow, DB
    Tohen, M
    Tollefson, GD
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S180 - S181
  • [33] EFFICACY OF THE COMBINATION OF FLUOXETINE AND PERPHENAZINE IN THE TREATMENT OF PSYCHOTIC DEPRESSION
    ROTHSCHILD, AJ
    SAMSON, JA
    BESSETTE, MP
    CARTERCAMPBELL, JT
    JOURNAL OF CLINICAL PSYCHIATRY, 1993, 54 (09) : 338 - 342
  • [34] Beyond the evidence: is there a place for antidepressant combinations in the pharmacotherapy of depression?
    Horgan, David P.
    MEDICAL JOURNAL OF AUSTRALIA, 2007, 187 (03) : 198 - 199
  • [35] Efficacy and effectiveness in the antidepressant treatment of depression: Beyond metaanalysis
    Kennedy, SH
    Bagby, RM
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1996, 41 (10): : 609 - 610
  • [36] Brain metabolite levels in remitted psychotic depression with consideration of effects of antipsychotic medication
    Tani, Hideaki
    Moxon-Emre, Iska
    Forde, Natalie J.
    Neufeld, Nicholas H.
    Bingham, Kathleen S.
    Whyte, Ellen M.
    Meyers, Barnett S.
    Alexopoulos, George S.
    Hoptman, Matthew J.
    Rothschild, Anthony J.
    Uchida, Hiroyuki
    Flint, Alastair J.
    Mulsant, Benoit H.
    Voineskos, Aristotle N.
    BRAIN IMAGING AND BEHAVIOR, 2024, 18 (01) : 117 - 129
  • [37] Brain metabolite levels in remitted psychotic depression with consideration of effects of antipsychotic medication
    Hideaki Tani
    Iska Moxon-Emre
    Natalie J. Forde
    Nicholas H. Neufeld
    Kathleen S. Bingham
    Ellen M. Whyte
    Barnett S. Meyers
    George S. Alexopoulos
    Matthew J. Hoptman
    Anthony J. Rothschild
    Hiroyuki Uchida
    Alastair J. Flint
    Benoit H. Mulsant
    Aristotle N. Voineskos
    Brain Imaging and Behavior, 2024, 18 : 117 - 129
  • [38] Evaluation of long acting, oral and combination antipsychotic treatments in patients with psychotic disorder
    Safak, Yasir
    Bulut, Suheyla Dogan
    Karadag, Hasan
    Orsel, Sibel
    KLINIK PSIKIYATRI DERGISI-TURKISH JOURNAL OF CLINICAL PSYCHIATRY, 2020, 23 (01): : 72 - 82
  • [39] SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study
    Davies, Simon J. C.
    Mulsant, Benoit H.
    Flint, Alastair J.
    Meyers, Barnett S.
    Rothschild, Anthony J.
    Whyte, Ellen M.
    Kirshner, Margaret M.
    Sorisio, Denise
    Pollock, Bruce G.
    Bies, Robert R.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2016, 31 (03) : 252 - 255
  • [40] Antidepressant and Antipsychotic Drugs
    Krystal, Andrew D.
    SLEEP MEDICINE CLINICS, 2010, 5 (04) : 571 - 589